Introduction During the last decades, biologics have revolutionized the treatment of Crohn's
disease and ulcerative colitis. Even though the inflammatory bowel disease (IBD) …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Tumor necrosis factor-α antibodies (anti-TNFs), termed “biologics,” have revolutionized the
medical management of moderate–severe inflammatory bowel disease. Randomized …

Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line
biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both “step …

Despite more than a decade of clinical experience in the treatment of inflammatory bowel
disease with biologic agents, particularly anti-tumor necrosis factor (TNF) antibodies, optimal …

Primary or secondary nonresponse to anti-TNF–α due to immunogenicity or treatment-
related side effects and the growing presence of innovative biological therapies targeting …

Despite the evolution in inflammatory bowel disease (IBD) management during the last 20
years owing to the advent of new advanced therapies, anti-TNF agents still remain the …

Background Failure of anti-TNF treatment in inflammatory bowel disease (IBD) patients can
take on several forms, each posing distinct etio-pathogenic considerations and management …

The advent of infliximab a decade ago has drastically changed the treatment paradigm for
patients with inflammatory bowel diseases (IBD). Controlled evidence supports the use of …

Tumor necrosis factor (TNF) antagonists are the cornerstone of therapy for moderately to
severely active inflammatory bowel disease (IBD). Although our understanding of …